Conference Coverage

Frailty stratifies pediatric liver disease severity


 

AT WCPGHAN 2016

– A newly devised measurement of frailty in children effectively determined the severity of liver disease in pediatric patients and might serve as a useful, independent predictor of outcomes following liver transplantations in children and adolescents.

The adapted pediatric frailty assessment formula is a “very valid, feasible, and valuable tool” for assessing children with chronic liver disease, Eberhard Lurz, MD, said at the World Congress of Pediatric Gastroenterology, Hepatology and Nutrition. “Frailty captures an additional marker of ill health that is independent of the MELD-Na [Model for End-Stage Liver Disease–Na] and PELD,” [Pediatric End-Stage Liver Disease] said Dr. Lurz, a pediatric gastroenterologist at the Hospital for Sick Children in Toronto.

Dr. Eberhard Lurz Mitchel L. Zoler/Frontline Medical News

Dr. Eberhard Lurz

“Frailty may be an additional marker [of suitability for liver transplantation], and every additional, objective marker is needed” when evaluating children for liver disease, but this new pediatric frailty score now needs validation, he said.

The idea of frailty assessment of children with liver disease sprang from a 2014 report that showed a five-item frailty index could predict mortality in adults with liver disease who were listed for liver transplantation and that this predictive power was independent of the patients’ MELD scores (Am J Transplant. 2014 Aug;14[8]:1870-9). That study used a five-item frailty index developed for adults (J Gerontol A Biol Sci Med Sci. 2001;56[3]:M146-57).

Dr. Lurz came up with a pediatric version of this frailty score using pediatric-oriented measures for each of the five items. To measure exhaustion he used the PedsQL (Pediatric Quality of Life Inventory) Multidimensional Fatigue Scale; for slowness he used a 6-minute walk test; for weakness he measured grip strength; for shrinkage he measured triceps skinfold thickness; and for diminished activity he used an age-appropriate physical activity questionnaire. He prespecified that a patient’s scores for each of these five measures are calculated by comparing their test results against age-specific norms. A patient with a value that fell more than one standard deviation below the normal range scores one point for the item and those with values more than two standard deviations below the normal range score two points. Hence the maximum score for all five items is 10.

Researchers at the collaborating centers completed full assessments for 71 of 85 pediatric patients with chronic liver disease in their clinics, and each full assessment took a median of 60 minutes. The patients ranged from 8-16 years old, with an average age of 13. The cohort included 36 patients with compensated chronic liver disease (CCLD) and 35 with end-stage liver disease (ESLD) who were listed for liver transplantation.

The median frailty score of the CCLD patients was 3 and the median score for those with ESLD was 5, a statistically significant difference that was largely driven by between-group differences in fatigue scores and physical activity scores. A receiver operating characteristic curve analysis by area under the curve showed that the frailty score accounted for 83% of the difference between patients with CCLD and ESLD, comparable to the distinguishing power of the MELD-Na score. Using a cutoff on the score of 6 or greater identified patients with ESLD with 47% sensitivity and 98% specificity, and this diagnostic capability was independent of a patient’s MELD-Na or PELD score.

The five elements that contribute to this pediatric frailty score could be the focus for targeted interventions to improve the outcomes of patients scheduled to undergo liver transplantation, Dr. Lurz said.

Dr. Lurz had no relevant financial disclosures.

On Twitter @mitchelzoler

Recommended Reading

Analysis yields ‘strong evidence’ for benefit of physical activity in NAFLD
MDedge Internal Medicine
Investigational HCV drug combo yields high SVR12 rates in compensated cirrhosis
MDedge Internal Medicine
Simple interventions markedly improve hepatitis care
MDedge Internal Medicine
Targeted HCV patients improve on sofosbuvir/daclatasvir combination
MDedge Internal Medicine
Direct-acting antivirals: One of several keys to HCV eradication by 2030
MDedge Internal Medicine
Nonalcoholic fatty liver disease estimated to cost $103 billion annually
MDedge Internal Medicine
Vitamin D deficiency linked to hepatitis B infection
MDedge Internal Medicine
Ombitasvir, paritaprevir, ritonavir, and dasabuvir in CKD patients with HCV
MDedge Internal Medicine
VIDEO: Harvoni shows safety, efficacy in adolescents for hepatitis C
MDedge Internal Medicine
Hepatitis Outlook: September 2016
MDedge Internal Medicine